Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 88% primary Improvement Relative Risk Mondal et al. Ivermectin for COVID-19 Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? Retrospective 1,470 patients in India Fewer symptomatic cases with ivermectin (p=0.006) Mondal et al., J. the Indian Medical Association, 119:5 Favors ivermectin Favors control

Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers: A Serosurvey Involving Multiple Hospitals in West Bengal

Mondal et al., Journal of the Indian Medical Association, 119:5
Mondal et al., Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers: A.., Journal of the Indian Medical Association, 119:5
May 2021   Source   PDF  
  All Studies   Meta
Retrospective 1,470 healthcare workers in India, showing significantly lower risk of symptomatic COVID-19 with ivermectin prophylaxis.
This is the 54th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.
risk of symptomatic case, 87.9% lower, RR 0.12, p = 0.006, treatment 128, control 1,342, adjusted per study, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, multivariable, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mondal et al., 31 May 2021, retrospective, India, peer-reviewed, 11 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers : A Serosurvey Involving Multiple Hospitals in West Bengal
Sunetra Mondal, Arijit Singha, Debaditya Das, Subhasis Neogi, Piyas Gargari, Moxit Shah, Durairaj Arjunan, Pradip Mukhopadhyay, Sujoy Ghosh, Jyothi Chowdhury, Subhankar Chowdhury
M ore than a hundred million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) over the past fourteen months. With the vaccination campaign targeting healthcare workers and the sudden decline in the daily number of cases in the country, the
Conflicts of interest : None Funding : None
Barrett, Horton, Roy, Gennaro, Brooks et al., Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers at the onset of the US COVID-19 epidemic, MedRxiv
Behera, Patro, Singh, Chandanshive, Ravikumar et al., Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study, medRxiv
Fang, Li, Yu, Wang, Zhang et al., Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and metaanalysis, Aging
Grant, Baggerly, Lahore, Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12 (4, Nutrients
Grasselli, Greco, Zanella, Albano, Antonelli et al., Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy, JAMA Internal Medicine
Gómez-Ochoa, Franco, Rojas, Raguindin, Roa-Díaz et al., COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes, American Journal of Epidemiology
Hawaldar, Sodani, Sodani, Sodani, Seroprevalence of COVID-19 infection among healthcare professionals in Central India using SARS-CoV-2 antibody test, The Journal of Community Health Management
Hernandez, Roman, Pasupuleti, Barboza, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Annals of Internal Medicine
Jayawardena, Sooriyaarachchi, Chourdakis, Jeewandara, Ranasinghe, Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes & Metabolic Syndrome, Clinical Research & Reviews
Kumar, Bhartiya, Desai, Mutha, Beldar et al., Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India, Asia Pacific Journal of Public Health
Kumar, Bhartiya, Desai, Mutha, Beldar et al., Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India, Asia Pacific Journal of Public Health
Kumar, Sathyapalan, Ramachandran, Subhash, Biswas et al., SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India, Clinical Microbiology and Infection
Lai, Wang, Qin, Tan, Ran et al., Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China, JAMA network open
Malone, Tisdall, Smith, Liu, Huang et al., -19: Famotidine, histamine, mast cells, and mechanisms
Meng, Zhao, Kumar, Bai, Deng, Impact of cardiovascular and metabolic diseases on the severity of COVID-19: a systematic review and meta-analysis, Aging
Murhekar, Bhatnagar, Selvaraju, Saravanakumar, Thangaraj et al., SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey, The Lancet Global Health
Nguyen, Drew, Joshi, Guo, Ma et al., Risk of COVID-19 among frontline healthcare workers, MedRxiv
Nuñez, Leon, Mucientes, Rodriguez-Rodriguez, Urgelles et al., Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases, Annals of the Rheumatic Diseases
Pal, Squitti, Picozza, Pawar, Rongioletti et al., Zinc and COVID-19: basis of current clinical trials, Biological Trace Element Research
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop